Overview

Erythropoietin Alfa in Elderly Subjects With Unexplained Anemia

Status:
Withdrawn
Trial end date:
2011-02-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to assess the ability of epoetin alfa to raise hemoglobin (Hb) levels in elderly outpatients with unexplained anemia. The secondary objectives of this study are to assess the ability of epoetin alfa to improve physical function; cognitive function; and quality of life, and to assess the safety of epoetin alfa in the study population.
Phase:
N/A
Details
Lead Sponsor:
Stanford University
Collaborator:
National Institute on Aging (NIA)
Treatments:
Epoetin Alfa